4982 KaiA/RbsU domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Organoheterocyclic compounds | 1 | 0.5 | 2.20× | not tested | |
| Organic oxygen compounds | 1 | 0.6 | 1.70× | not tested | |
| Homogeneous non-metal compounds | 1 | 0.6 | 1.57× | not tested | |
| Homogeneous metal compounds | 1 | 1.5 | 0.69× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB04646 | BNT | Dibromothymoquinone | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| 52M | 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-[(sulfanylcarbonyl)amino]benzoic acid | 2 |
| BNT | 2,5-DIBROMO-3-ISOPROPYL-6-METHYLBENZO-1,4-QUINONE | 2 |
| XE | XENON | 1 |
| ZNmetal | ZINC ION | 1 |